

Peter W M Johnson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8285309/peter-w-m-johnson-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

243
papers

13,933
citations

64
h-index

114
g-index

265
ext. papers

16,397
ext. citations

6.1
avg, IF

6.04
L-index

#	Paper	IF	Citations
243	Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study.. <i>Nature Cancer</i> , 2022 ,	15.4	5
242	Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204). <i>Blood</i> , 2021 , 138, 44-44	2.2	0
241	Selinexor Enhances NK Cell Activation Against Malignant B Cells Downregulation of HLA-E.. <i>Frontiers in Oncology</i> , 2021 , 11, 785635	5.3	0
240	KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. <i>Blood</i> , 2021 , 138, 370-381	2.2	16
239	Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs. <i>Current Oncology Reports</i> , 2021 , 23, 76	6.3	
238	Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP+ibrutinib. <i>British Journal of Haematology</i> , 2021 , 194, 83-91	4.5	2
237	Personalized medicine for Hodgkin lymphoma: Mitigating toxicity while preserving cure. <i>Hematological Oncology</i> , 2021 , 39 Suppl 1, 39-45	1.3	0
236	Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial. <i>British Journal of Haematology</i> , 2021 , 192, 1015-1019	4.5	2
235	Comparative analysis of gene expression platforms for cell-of-origin classification of diffuse large B-cell lymphoma shows high concordance. <i>British Journal of Haematology</i> , 2021 , 192, 599-604	4.5	3
234	The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis. <i>Lancet Oncology, The</i> , 2021 , 22, 66-73	21.7	17
233	Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. <i>Blood</i> , 2021 , 137, 637-645	2.2	31
232	Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial. <i>Annals of Hematology</i> , 2021 , 100, 1049-1058	3	2
231	Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma. <i>Lancet Haematology,the</i> , 2021 , 8, e542-e544	14.6	37
230	Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. <i>BMJ, The</i> , 2021 , 374, n2244	5.9	38
229	Resources-Stratified Guidelines for Classical Hodgkin Lymphoma. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	4
228	Progressive multifocal leukoencephalopathy (PML) following autologous peripheral blood stem cell transplantation for multiple myeloma. <i>Clinical Case Reports (discontinued)</i> , 2020 , 8, 938-943	0.7	3
227	Health-related quality-of-life results from the phase 3 OPTIMISM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1850-1859	1.9	4

226	Interim Cell-Free Circulating Lymphoma DNA Analysis of the Phase 2 Accept Trial. <i>Blood</i> , 2020 , 136, 24-25.2		
225	Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204). <i>Blood</i> , 2020 , 136, 27-28	2.2	4
224	Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data. <i>Blood</i> , 2020 , 136, 45-46	2.2	29
223	Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study. <i>Blood</i> , 2020 , 136, 38-39	2.2	1
222	Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. <i>Blood</i> , 2020 , 136, 16-18	2.2	1
221	Treatment of Advanced-Stage Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2020 , 249-264	0	
220	Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit. <i>Leukemia</i> , 2020 , 34, 1329-1341	10.7	20
219	Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. <i>BMJ, The</i> , 2020 , 371, m3731	5.9	226
218	BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression. <i>Blood Advances</i> , 2020 , 4, 3316-3328	7.8	12
217	BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia. <i>Leukemia</i> , 2020 , 34, 640-644	10.7	6
216	Molecular MRD status and outcome after transplantation in NPM1-mutated AML. <i>Blood</i> , 2020 , 135, 680-688	6.8	58
215	Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma. <i>Blood Advances</i> , 2020 , 4, 203-206	7.8	10
214	Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2020 , 105, 318-321	6.6	2
213	Options for first line therapy of Hodgkin lymphoma. <i>Hematological Oncology</i> , 2019 , 37 Suppl 1, 82-86	1.3	6
212	Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1732-1741	2.2	26
211	Focal skeletal FDG uptake indicates poor prognosis in cHL regardless of extent and first-line chemotherapy. <i>British Journal of Haematology</i> , 2019 , 186, 431-439	4.5	6
210	Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 649-662	21.7	95
209	Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 481-489	2.2	173

208	Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy. <i>Journal of Clinical Oncology</i> , 2019 , 37, 202-212	2.2	99
207	Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1285-1295	2.2	188
206	Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplant. <i>Haematologica</i> , 2019 , 104, e174-e177	6.6	4
205	Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 7331-7339	12.9	55
204	First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody [®] -CD3 ⁺ CD20) in B-Cell Non-Hodgkin Lymphomas. <i>Blood</i> , 2019 , 134, 758-758	2.2	16
203	Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2019 , 134, 761-761	2.2	6
202	Clinical Impact of Ibrutinib with R-CHOP in Untreated Non-GCB DLBCL Co-Expressing BCL2 and MYC Genes in the Phase 3 Phoenix Trial. <i>Blood</i> , 2019 , 134, 354-354	2.2	6
201	High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade during Ibrutinib Therapy in CLL Patients. <i>Blood</i> , 2019 , 134, 1752-1752	2.2	2
200	Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel. <i>Blood</i> , 2019 , 134, 2769-2769	2.2	2
199	Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 1334-1344	8.8	8
198	Current treatment paradigms for advanced stage Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019 , 184, 60-71	4.5	2
197	Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients. <i>Clinical Cancer Research</i> , 2019 , 25, 2503-2512	12.9	14
196	Optimizing therapy in advanced-stage Hodgkin lymphoma. <i>Blood</i> , 2018 , 131, 1679-1688	2.2	16
195	CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. <i>Lancet Haematology</i> , 2018 , 5, e190-e200	14.6	33
194	Does PET Reconstruction Method Affect Deauville Scoring in Lymphoma Patients?. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1167-1169	8.9	19
193	Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. <i>Leukemia</i> , 2018 , 32, 1261-1265	10.7	58
192	Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking. <i>Scientific Reports</i> , 2018 , 8, 2278	4.9	16
191	Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes. <i>British Journal of Haematology</i> , 2018 , 182, 212-221	4.5	7

190	Variable Responses of MYC Translocation Positive Lymphoma Cell Lines To Different Combinations of Novel Agents: Impact of BCL2 Family Protein Expression. <i>Translational Oncology</i> , 2018 , 11, 1147-1154	4.9	6
189	The iR2 Regimen(Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018 , 132, 402-402	2.2	2
188	A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial. <i>Blood</i> , 2018 , 132, 2956-2956	2.2	1
187	Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimism Study. <i>Blood</i> , 2018 , 132, 1960-1960	2.2	1
186	A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2018 , 132, 784-784	2.2	13
185	Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study. <i>Blood</i> , 2018 , 132, 4097-4097	2.2	3
184	All that glitters is not gold - new reconstruction methods using Deauville criteria for patient reporting. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 316-317	8.8	16
183	Controversies in the Treatment of Classical Hodgkin Lymphoma. <i>HemaSphere</i> , 2018 , 2, e149	0.3	6
182	RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial. <i>Trials</i> , 2018 , 19, 619	2.8	4
181	Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 ⁺ T Cell Effector Function. <i>Immunity</i> , 2018 , 49, 958-970.e7	32.3	72
180	Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. <i>ESMO Open</i> , 2018 , 3, e000408	6	2
179	Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 1328-1337	21.7	40
178	Mutation screening using formalin-fixed paraffin-embedded tissues: a stratified approach according to DNA quality. <i>Laboratory Investigation</i> , 2018 , 98, 1084-1092	5.9	6
177	Primary mediastinal large B-cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 113, 318-327		45
176	Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study. <i>British Journal of Haematology</i> , 2017 , 178, 588-591	4.5	15
175	Response-adapted therapy in Hodgkin lymphoma. <i>Hematological Oncology</i> , 2017 , 35 Suppl 1, 33-36	1.3	0
174	Should Response-Adapted Therapy Now Be the Standard of Care for Advanced Hodgkin's Lymphoma?. <i>Current Treatment Options in Oncology</i> , 2017 , 18, 15	5.4	4
173	In Reply to Adams and Kwee. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 97, 870-871		

172	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology</i> , 2017 , 4, e510-e523	14.6	157
171	Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, S380-S381	2	2
170	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1905-1912	2.2	98
169	Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. <i>Haematologica</i> , 2017 , 102, 1748-1757	6.6	31
168	A MALT lymphoma prognostic index. <i>Blood</i> , 2017 , 130, 1409-1417	2.2	96
167	F-FDG PET/CT in Lymphoma: Has Imaging-Directed Personalized Medicine Become a Reality?. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1539-1544	8.9	21
166	Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment. <i>Cancer Cell</i> , 2017 , 32, 777-791.e6	24.3	35
165	Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 97, 42-49	4	21
164	The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017 , 23, 2313-2324	12.9	35
163	The Use of Anti-CD40 mAb in Cancer. <i>Current Topics in Microbiology and Immunology</i> , 2017 , 405, 165-207	3.3	16
162	IL-4 enhances expression and function of surface IgM in CLL cells. <i>Blood</i> , 2016 , 127, 3015-25	2.2	55
161	The European Cancer Patient's Bill of Rights, update and implementation 2016. <i>ESMO Open</i> , 2016 , 1, e000127	6	25
160	The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. <i>Haematologica</i> , 2016 , 101, 235-40	6.6	21
159	Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2016 , 374, 2419-29	59.2	428
158	Treatment of advanced-stage Hodgkin lymphoma. <i>Seminars in Hematology</i> , 2016 , 53, 171-9	4	20
157	The European Hematology Association Roadmap for European Hematology Research: a consensus document. <i>Haematologica</i> , 2016 , 101, 115-208	6.6	46
156	Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. <i>Nature Genetics</i> , 2016 , 48, 183-8	3.3	116
155	The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma As Determined By Whole Genome Expression Profiling on Paraffin Embedded Tissue Is Independently Associated with Reduced Overall and Progression Free Survival in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Phase III Trial. <i>Blood</i> , 2016 , 128, 1716-1716	2.2	5

154	A phase I, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkin lymphomas (NHL), multiple myeloma (MM) and solid tumor.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS2595-TPS2595.	2.2	10
153	Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. <i>British Journal of Haematology</i> , 2016 , 173, 274-82	4.5	11
152	Lymphoma: turning biology into cures. <i>Clinical Medicine</i> , 2016 , 16, s125-s129	1.9	5
151	Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?. <i>Hematology American Society of Hematology Education Program</i> , 2016 , 2016, 316-322	3.1	15
150	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. <i>Lancet Haematology</i> , 2016 , 3, e217-27	14.6	288
149	HD2000 Update in Hodgkin Lymphoma-ABVD or BEACOPP?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3584-3585	3.5	1
148	PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. <i>Blood</i> , 2016 , 127, 1531-8	2.2	105
147	Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. <i>British Journal of Haematology</i> , 2016 , 175, 668-672	4.5	29
146	The prognosis of translocation positive diffuse large B-cell lymphoma depends on the second hit. <i>Journal of Pathology: Clinical Research</i> , 2015 , 1, 125-133	5.3	40
145	Principles of Chemotherapy in Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2015 , 177-199	0	
144	Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. <i>New England Journal of Medicine</i> , 2015 , 372, 1598-607	59.2	437
143	Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. <i>Cancer Cell</i> , 2015 , 27, 473-88	24.3	84
142	Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study. <i>Clinical Cancer Research</i> , 2015 , 21, 1321-8	12.9	57
141	Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98). <i>British Journal of Haematology</i> , 2015 , 168, 145-8	4.5	29
140	A collaborative approach to enabling stratified cancer medicine in the UK. <i>Drug Discovery Today</i> , 2015 , 20, 1414-8	8.8	6
139	How I treat advanced classical Hodgkin lymphoma. <i>Blood</i> , 2015 , 125, 1717-23	2.2	18
138	The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eμ-TCL1 mouse model. <i>Blood</i> , 2015 , 125, 4032-41	2.2	28
137	Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. <i>Blood</i> , 2015 , 126, 950-6	2.2	111

136	Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. <i>Blood</i> , 2015 , 126, 739-45	2.2	268
135	Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?. <i>BioMed Research International</i> , 2015 , 2015, 865101	3	13
134	IV. Masses in the mediastinum: primary mediastinal lymphoma and intermediate types. <i>Hematological Oncology</i> , 2015 , 33 Suppl 1, 29-32	1.3	16
133	Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 2524-34	27.4	102
132	Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 483-8	4.7	4
131	Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. <i>Cancer Cell</i> , 2015 , 27, 138-48	24.3	99
130	R-CHOP in Primary Mediastinal B-Cell Lymphoma (PMBL): Results from the UK NCRI R-CHOP 14 v 21 Trial. <i>Blood</i> , 2015 , 126, 2689-2689	2.2	2
129	A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425). <i>Blood</i> , 2015 , 126, 812-812	2.2	19
128	Defining Immune Response Signatures in DLBCL As Potential Predictive Biomarkers for Outcome to Immunotherapy. <i>Blood</i> , 2015 , 126, 2663-2663	2.2	
127	Real-Time Molecular Classification of Diffuse Large B-Cell Lymphoma (DLBCL) By Gene Expression Profiling (GEP): Successful Delivery of a Routine Service for Randomization of Patients Onto the Multicenter Remodl-B Trial (ISRCTN 51837425). <i>Blood</i> , 2015 , 126, 331-331	2.2	
126	Risk- and response-adapted strategies for the management of Hodgkin lymphoma. <i>Chinese Clinical Oncology</i> , 2015 , 4, 13	2.3	4
125	[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1769-75	2.2	120
124	Differential impact of CD27 and 4-1BB costimulation on effector and memory CD8 T cell generation following peptide immunization. <i>Journal of Immunology</i> , 2014 , 193, 244-51	5.3	35
123	Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization. <i>Journal of Immunology</i> , 2014 , 193, 1828-35	5.3	45
122	Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas. <i>Immunotherapy</i> , 2014 , 6, 1187-2008	2.2	19
121	A national platform for molecular diagnostics: Results of the Cancer Research U.K. Stratified Medicine Programme.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11079-11079	2.2	1
120	A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS8615-TPS8615	2.2	8
119	Primary Mediastinal Large B-Cell Lymphoma 2014 , 195-206		1

118 Antibody Therapy in Oncology **2014**, 101-110

117	Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. <i>British Journal of Haematology</i> , 2013 , 162, 107-11	4.5	45
116	Fc γ BB controls the potency of agonistic anti-TNFR mAbs. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 941-8	7.4	33
115	Expression of inhibitory Fc receptor (Fc γ RIIB) is a marker of poor response to rituximab monotherapy in follicular lymphoma. <i>Lancet, The</i> , 2013 , 381, S63	4.0	2
114	Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. <i>New England Journal of Medicine</i> , 2013 , 369, 507-16	59.2	1139
113	Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 565-72	2.2	161
112	Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. <i>Lancet, The</i> , 2013 , 381, 1817-26	4.0	354
111	Novel antibodies targeting immune regulatory checkpoints for cancer therapy. <i>British Journal of Clinical Pharmacology</i> , 2013 , 76, 233-47	3.8	31
110	Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cells. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 1093-105	7.4	10
109	A novel adaptive trial design: randomised evaluation of molecular guided therapy for diffuse large b-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore safety and efficacy. <i>Trials</i> , 2013 , 14,	2.8	78
108	Management of early-stage Hodgkin lymphoma: is there still a role for radiation?. <i>Hematology American Society of Hematology Education Program</i> , 2013 , 2013, 400-5	3.1	8
107	III. Applying molecular phenotyping in practice. <i>Hematological Oncology</i> , 2013 , 31 Suppl 1, 29-32	1.3	5
106	Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. <i>Journal of Clinical Oncology</i> , 2013 , 31, 573-83	2.2	124
105	Is there a role for consolidation radiotherapy in Hodgkin lymphoma in the era of the PET scan?. <i>International Journal of Hematologic Oncology</i> , 2013 , 2, 27-38	1	
104	Utilizing a collaborative working model to optimize molecular analysis of solid tumors in the Cancer Research UK's Stratified Medicine Programme.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 11094-11094	2.2	2
103	Patients With DLBCL Commonly Have B-Cell Lymphopenia and Circulating Clonal B-Cell Populations With a Phenotype Concordant With The Underlying Tumour. <i>Blood</i> , 2013 , 122, 3013-3013	2.2	
102	A Universal Lectin-Mediated Interaction Drives B-Cell Receptor Signaling In Primary Follicular Lymphoma Cells. <i>Blood</i> , 2013 , 122, 4291-4291	2.2	
101	Stratified medicine for cancer therapy. <i>Drug Discovery Today</i> , 2012 , 17, 261-8	8.8	5

100	A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancer. <i>Chemotherapy</i> , 2012 , 58, 257-63	3.2	5
99	Role of Positron Emission Tomography (PET/CT) in Primary Mediastinal Large B Cell Lymphoma (PMLBCL): Preliminary Results of an International Phase II Trial (IELSG-26 Study) Conducted On Behalf of the International Extranodal Lymphoma Study Group (IELSG), the Fondazione Italiana Linfomi (FIL) and the UK NCRI Lymphoma Group. <i>Blood</i> , 2012 , 120, 1566-1566	2.2	2
98	Emerging findings in the Cancer Research UK stratified medicine program.. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS10633-TPS10633	2.2	1
97	A Phase 1 Trial of Escalating High Dose Methotrexate Supported by Glucarpidase to Treat Patients with Primary Central Nervous System Lymphoma (PCNSL). (CRUK/08/010). <i>Blood</i> , 2012 , 120, 4850-4850	2.2	1
96	Expression of Inhibitory Fc Receptor (FcRIIB) Is a Marker of Poor Response to Rituximab Monotherapy in Follicular Lymphoma (FL).. <i>Blood</i> , 2012 , 120, 2747-2747	2.2	
95	Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. <i>Blood</i> , 2011 , 118, 2530-40	2.2	175
94	S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 109-19	4.4	86
93	Prediction of single-nucleotide substitutions that result in exon skipping: identification of a splicing silencer in BRCA1 exon 6. <i>Human Mutation</i> , 2011 , 32, 436-44	4.7	85
92	Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. <i>Annals of Oncology</i> , 2011 , 22, 739-745	10.3	53
91	Principles of Chemotherapy in Hodgkin Lymphoma 2011 , 141-161		1
90	Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2010 , 151, 346-53	4.5	57
89	Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519). <i>Annals of Oncology</i> , 2010 , 21, 568-573	10.3	11
88	Harnessing innate immunity to suppress lymphoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4295-6	2.2	4
87	Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 18587-92	11.5	123
86	Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). <i>Journal of Clinical Oncology</i> , 2010 , 28, 3352-9	2.2	61
85	The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival. <i>Cancer Biology and Therapy</i> , 2010 , 10, 728-35	4.6	57
84	Anti-CD20 monoclonal antibodies: historical and future perspectives. <i>Haematologica</i> , 2010 , 95, 135-43	6.6	203
83	Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. <i>Blood</i> , 2010 , 115, 5191-201	2.2	245

82	Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010 , 37, 1824-33	8.8	235
81	Enumeration and phenotypic assessment of human plasmacytoid and myeloid dendritic cells in whole blood. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2010 , 77, 328-37	4.6	11
80	Cancer Research UK promotes research in surgery. <i>Bulletin of the Royal College of Surgeons of England</i> , 2009 , 91, 194-195	0.5	
79	Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5390-6	2.2	139
78	Thioflavin S (NSC71948) interferes with Bcl-2-associated athanogene (BAG-1)-mediated protein-protein interactions. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009 , 331, 680-9	4.7	27
77	Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. <i>Journal of Immunological Methods</i> , 2009 , 340, 55-64	2.5	199
76	Short peptides derived from the BAG-1 C-terminus inhibit the interaction between BAG-1 and HSC70 and decrease breast cancer cell growth. <i>FEBS Letters</i> , 2009 , 583, 3405-11	3.8	13
75	Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. <i>Blood</i> , 2009 , 113, 1412-21	2.2	75
74	Interim Analysis of the IELSG-19 Randomised Study of Chlorambucil Alone Versus Chlorambucil Plus Rituximab Versus Rituximab Alone in Extranodal Marginal Zone Lymphomas of Mucosa-Associated Lymphoid Tissue (MALT lymphoma).. <i>Blood</i> , 2009 , 114, 3939-3939	2.2	1
73	Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or 'Aggressive' Lymphoma.. <i>Blood</i> , 2009 , 114, 584-584	2.2	16
72	Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?. <i>British Journal of Cancer</i> , 2008 , 99, 689-94	8.7	76
71	Survival from non-Hodgkin lymphoma in England and Wales up to 2001. <i>British Journal of Cancer</i> , 2008 , 99 Suppl 1, S107-9	8.7	6
70	Intestinal strictures: a new complication of treatment for primary gastrointestinal diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2008 , 140, 712-4	4.5	4
69	Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A. <i>Biochemical Pharmacology</i> , 2008 , 76, 463-75	6	61
68	Primary mediastinal B-cell lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2008 , 349-58	3.1	57
67	Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. <i>Journal of Biological Chemistry</i> , 2008 , 283, 16971-84	5.4	108
66	First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. <i>Blood</i> , 2008 , 111, 5486-95	2.2	223
65	Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies. <i>European Journal of Immunology</i> , 2008 , 38, 2499-511	6.1	46

64	Primary mediastinal large B-cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 68, 256-63	7	53
63	Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in Patients with Clinical Stages 1A and 2A Hodgkin Lymphoma and a Negative FDG-PET Scan after 3 Cycles ABVD. <i>Blood</i> , 2008 , 112, 369-369	2.2	14
62	Randomised Comparison of the Stanford V (SV) Regimen and ABVD in the Treatment of Advanced Hodgkin Lymphoma (HL): Results from a UK NCRI Lymphoma Group Study, ISRCTN 64141244. <i>Blood</i> , 2008 , 112, 370-370	2.2	7
61	BAG-1 inhibits PPARgamma-induced cell death, but not PPARgamma-induced transcription, cell cycle arrest or differentiation in breast cancer cells. <i>Oncology Reports</i> , 2008 , 19, 689-96	3.5	10
60	Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells. <i>Oncogene</i> , 2007 , 26, 1166-77	9.2	66
59	Microscopic intratumoral dosimetry of radiolabeled antibodies is a critical determinant of successful radioimmunotherapy in B-cell lymphoma. <i>Cancer Research</i> , 2007 , 67, 1335-43	10.1	10
58	Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. <i>Blood</i> , 2007 , 109, 4810-5	2.2	83
57	Breast cancer is a promising target for vaccination using cancer-testis antigens known to elicit immune responses. <i>Breast Cancer Research</i> , 2007 , 9, R46	8.3	20
56	Late Events in Patients with Relapsed or Refractory Hodgkin's Lymphoma Treated with an Autologous Stem Cell Transplantation.. <i>Blood</i> , 2007 , 110, 834-834	2.2	
55	Multi-Center Phase II Study of CAMPATH-1H Dose De-Escalation Prior to Nonmyeloablative HLA-Identical Sibling Transplantation.. <i>Blood</i> , 2007 , 110, 1055-1055	2.2	1
54	Comparison of outcomes in studies of advanced Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3309; author reply 3309-10	2.2	
53	Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2105-12	2.2	151
52	Therapeutic potential of immunostimulatory monoclonal antibodies. <i>Clinical Science</i> , 2006 , 111, 93-106	6.5	13
51	Immunohistochemical analysis of the antiapoptotic Mcl-1 and Bcl-2 proteins in follicular lymphoma. <i>British Journal of Haematology</i> , 2006 , 132, 743-6	4.5	17
50	The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. <i>British Journal of Haematology</i> , 2006 , 134, 385-90	4.5	46
49	Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. <i>Investigational New Drugs</i> , 2006 , 24, 223-31	4.3	39
48	Zanolimumab, a Fully Human Monoclonal Antibody: Preliminary Results of an Ongoing Clinical Trial in CD4+ Peripheral T-Cell Lymphomas (PTCL).. <i>Blood</i> , 2006 , 108, 2723-2723	2.2	1
47	A Phase II Study (BioV-121) of Clofarabine Monotherapy First Line in Patients Aged 65 Years or Older with Acute Myeloid Leukemia for Whom Standard Intensive Chemotherapy Is Not Considered Suitable.. <i>Blood</i> , 2006 , 108, 425-425	2.2	14

46	Mcl-1. <i>International Journal of Biochemistry and Cell Biology</i> , 2005 , 37, 267-71	5.6	191
45	Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. <i>Journal of Clinical Oncology</i> , 2005 , 23, 142-53	2.2	133
44	Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). <i>Journal of Clinical Oncology</i> , 2005 , 23, 9208-18	2.2	115
43	Targeted Radiotherapy in the Conditioning Prior to Haematopoietic Stem Cell Transplantation: Results of a Phase I Radiation Dose Escalation Study Using Yttrium-90-Labelled Anti-CD66 Monoclonal Antibody Demonstrating High BM Uptake of Radiation.. <i>Blood</i> , 2005 , 106, 2189-2189	2.2	1
42	Current strategies to target the anti-apoptotic Bcl-2 protein in cancer cells. <i>Current Medicinal Chemistry</i> , 2004 , 11, 1031-9	4.3	33
41	DNA vaccines to attack cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101 Suppl 2, 14646-52	11.5	100
40	Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. <i>Oncogene</i> , 2004 , 23, 4818-27	9.2	121
39	Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. <i>Blood</i> , 2004 , 103, 1485-94	2.2	18
38	Prediction of Response to Recombinant Erythropoietin Plus Granulocyte-Colony Stimulating Factor Following a Single Subcutaneous Bolus in Patients with Myelodysplastic Syndromes; a Randomised Placebo Controlled Study.. <i>Blood</i> , 2004 , 104, 1435-1435	2.2	1
37	Stanford V (SV) Regimen Versus ABVD for the Treatment of Advanced Hodgkin Lymphoma (HL): Results of a UK NCRI/LTO Randomised Phase II Trial.. <i>Blood</i> , 2004 , 104, 311-311	2.2	
36	Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. <i>Blood</i> , 2003 , 101, 1045-52	2.2	303
35	Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. <i>Blood</i> , 2003 , 102, 1449-57	2.2	73
34	Hdm2 Recruits the Hypoxia Sensitive Transcriptional Co-Repressor CtBP2 to Negatively Regulate p53-Dependant Transcription. <i>Clinical Science</i> , 2003 , 104, 29P-29P		
33	Differential regulation of cell survival by CD40. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2003 , 8, 45-53	5.4	41
32	Hdm2 recruits a hypoxia-sensitive corepressor to negatively regulate p53-dependent transcription. <i>Current Biology</i> , 2003 , 13, 1234-9	6.3	63
31	The mechanisms of action of rituximab in the elimination of tumor cells. <i>Seminars in Oncology</i> , 2003 , 30, 3-8	5.5	166
30	The nuclear BAG-1 isoform, BAG-1L, enhances oestrogen-dependent transcription. <i>Oncogene</i> , 2003 , 22, 4973-82	9.2	57
29	Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. <i>American Journal of Pathology</i> , 2003 , 162, 243-53	5.8	137

28	Spontaneous clinical regression in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2002 , 116, 341-345	4.5	28
27	CD40 induces interleukin-6 gene transcription in dendritic cells: regulation by TRAF2, AP-1, NF-kappa B, AND CBF1. <i>Journal of Biological Chemistry</i> , 2002 , 277, 17125-38	5.4	76
26	The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 1381-95	9.7	48
25	Mechanism of action of rituximab. <i>Anti-Cancer Drugs</i> , 2002 , 13 Suppl 2, S3-10	2.4	113
24	Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. <i>Blood</i> , 2002 , 99, 2562-8	2.2	202
23	Molecular remission and non-Hodgkin's lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2002 , 15, 549-62	4.2	7
22	Rituximab: mechanisms and applications. <i>British Journal of Cancer</i> , 2001 , 85, 1619-23	8.7	73
21	The therapeutic use of antibodies for malignancy. <i>Transfusion Clinique Et Biologique</i> , 2001 , 8, 255-9	1.9	5
20	A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. <i>British Journal of Haematology</i> , 2000 , 109, 81-8	4.5	89
19	Clinical trials of antibody therapy. <i>Trends in Immunology</i> , 2000 , 21, 403-10		243
18	Identification of a novel human BCL-X promoter and exon. <i>Oncogene</i> , 2000 , 19, 5534-8	9.2	14
17	Persistence of clonal T-cell expansions following high-dose chemotherapy and autologous peripheral blood progenitor cell rescue. <i>British Journal of Haematology</i> , 2000 , 111, 766-773	4.5	
16	High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. <i>Journal of Clinical Oncology</i> , 2000 , 18, 527-36	2.2	155
15	European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. <i>Journal of Clinical Oncology</i> , 2000 , 18, 317-24	2.2	404
14	Persistence of clonal T-cell expansions following high-dose chemotherapy and autologous peripheral blood progenitor cell rescue. <i>British Journal of Haematology</i> , 2000 , 111, 766-773	4.5	5
13	Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. <i>British Journal of Cancer</i> , 1999 , 79, 509-14	8.7	57
12	A stimulating new target for cancer immunotherapy. <i>Lancet, The</i> , 1999 , 354, 1225-7	4.0	15
11	Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study. <i>Annals of Oncology</i> , 1999 , 10, 1349-54	10.3	31

10	Allele imbalance at tumour suppressor loci during the indolent phase of follicle centre cell lymphoma. <i>Leukemia and Lymphoma</i> , 1996 , 22, 113-7, follow. 186, color plate X	1.9	
9	Effects of interleukin 6 administration on platelets and haemopoietic progenitor cells in peripheral blood. <i>Cytokine</i> , 1996 , 8, 717-23	4	24
8	Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. <i>British Journal of Cancer</i> , 1996 , 74, 463-7	8.7	78
7	The molecular detection of circulating tumour cells. <i>British Journal of Cancer</i> , 1995 , 72, 268-76	8.7	139
6	Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. <i>Journal of Clinical Oncology</i> , 1995 , 13, 140-7	2.2	293
5	Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. <i>Journal of Clinical Oncology</i> , 1994 , 12, 798-805	2.2	79
4	Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. <i>Journal of Clinical Oncology</i> , 1994 , 12, 1177-84	2.2	186
3	A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. <i>Journal of Clinical Oncology</i> , 1994 , 12, 1427-35	2.2	99
2	KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas		1
1	Protocol for the development and evaluation of a tool for predicting risk of short-term adverse outcomes due to COVID-19 in the general UK population		4